Fig. 8: Senolytic treatment enhances the response to immune checkpoint therapy. | Nature Communications

Fig. 8: Senolytic treatment enhances the response to immune checkpoint therapy.

From: Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma restrict CD8+ T cell activation and limit responsiveness to immunotherapy in mice

Fig. 8

a Diagram of experimental design. 6422c1 KPC tumor cells were injected into mouse pancreata. Mice were treated with ABT-199, with ICT including αCTLA4, αPD1 and αCD40, or with both treatment types. b H&E-stained images of representative pancreatic tissues in mice treated with the different protocols. Dark regions represent remaining normal acinar tissue (white arrows). Tumor lesions in ABT + ICT mice are indicated by black arrows. Scale bar = 1 mm. c Pancreatic tissue weights upon mouse sacrifice in the different treatment mouse groups. Note that weights in ICT and ABT + ICT groups include some remaining normal tissue. n = 10 UNT, n = 6 ABT, n = 11 ICT, n = 12 ABT + ICT. d Higher magnification of H&E-stained tumor regions shown in (b). Dashed line indicates necrotic region in ABT + ICT-treated tumor. Scale bar = 100 μm. e Percentage of necrotic area out of tumor lesion area in the different treatment groups. Tissues that did not contain any remaining tumor lesions were not included. n = 10 UNT, n = 5 ABT, n = 9 ICT, n = 8 ABT + ICT. f Stain of tumor lesions for YFP in same, marking carcinoma cells with lesions. Scale bar = 100 μm. g Percentage of lesion area stained for YFP, indicating carcinoma cells, in the different treatment groups. n = 8 UNT, n = 6 ABT, n = 9 ICT, n = 8 ABT + ICT. All values indicate mean ± SEM. P values were calculated with Brown-Forsythe ANOVA test and Benjamini-Hochberg false discovery rate correction.

Back to article page